William Blair Begins Coverage on Denali Therapeutics (NASDAQ:DNLI)

Stock analysts at William Blair assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI) in a report issued on Friday, MarketBeat Ratings reports. The brokerage set an “outperform” rating on the stock.

Several other brokerages also recently commented on DNLI. Stifel Nicolaus upgraded shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a report on Monday, December 16th. JPMorgan Chase & Co. decreased their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. HC Wainwright reissued a “buy” rating and issued a $90.00 price objective on shares of Denali Therapeutics in a research report on Thursday, November 7th. Jefferies Financial Group raised their target price on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Finally, Cantor Fitzgerald cut shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $40.40.

Denali Therapeutics Stock Up 2.0 %

Shares of DNLI stock opened at $21.26 on Friday. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $33.33. The firm has a fifty day moving average of $24.62 and a 200-day moving average of $24.88. The firm has a market capitalization of $3.06 billion, a price-to-earnings ratio of -7.70 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter in the previous year, the business earned ($0.72) earnings per share. Research analysts expect that Denali Therapeutics will post -2.71 earnings per share for the current year.

Insider Transactions at Denali Therapeutics

In other news, Director Vicki L. Sato sold 1,020 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $30.00, for a total value of $30,600.00. Following the transaction, the director now directly owns 111,056 shares of the company’s stock, valued at $3,331,680. This represents a 0.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Alexander O. Schuth sold 15,558 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $29.91, for a total transaction of $465,339.78. Following the sale, the insider now owns 178,066 shares of the company’s stock, valued at approximately $5,325,954.06. This represents a 8.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 59,658 shares of company stock worth $1,667,943 in the last ninety days. Insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its holdings in shares of Denali Therapeutics by 6.5% during the third quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company’s stock worth $6,857,000 after acquiring an additional 14,324 shares during the period. Principal Financial Group Inc. lifted its holdings in Denali Therapeutics by 13.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock worth $36,076,000 after purchasing an additional 149,939 shares during the last quarter. Franklin Resources Inc. boosted its stake in Denali Therapeutics by 3.8% in the 3rd quarter. Franklin Resources Inc. now owns 80,041 shares of the company’s stock valued at $2,148,000 after purchasing an additional 2,901 shares during the period. Barclays PLC grew its holdings in Denali Therapeutics by 101.4% in the 3rd quarter. Barclays PLC now owns 255,883 shares of the company’s stock valued at $7,454,000 after buying an additional 128,823 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. bought a new position in Denali Therapeutics during the 3rd quarter worth $1,894,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.